An orthotopic bladder cancer mouse model was established to evaluate the <i>in vivo</i> effects of a YAP inhibitor (verteporfin) and a PDGFR inhibitor (CP-673451) on the <i>cis</i>-platinum resistance of OV6<sup>+</sup> CSCs in bladder cancer.
In addition, c-MET network gene (c-MET, AXL, and PDGFR) expression allowed discrimination of BCa tissues from normal control tissues and appeared to predict poor disease progression in non-muscle invasive BCa patients and poor overall survival in muscle invasive BCa patients.
We transfected the nonplatelet-derived growth factor receptor-β expressing bladder cancer cell line UMUC5 with the platelet-derived growth factor receptor-β gene.